Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

TheMotleyFool

0 0

Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

It's been a really good year for Exelixis (NASDAQ: EXEL). The biotech's share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But it's been a really great year for Immunogen (NASDAQ: IMGN): The stock has soared nearly 270%.

The past is the past, though. Which of these cancer-focused biotech stocks is the better choice for investors now? Here's how Exelixis and Immunogen compare.

Image source: Getty Images.

Source: Fool.com